Pulmonary function three to five months after hospital discharge for COVID-19: a single centre cohort study

T. Krueger; J. van den Heuvel; V. van van den Boogaart; R. van Zeeland; D.J. Mehagnoul-Schipper; D.G. Barten; L. Knarren; A.F.G. Maas; C.E. Wyers; D. Gach; A.M.W.J. Schols; R.J.H.C.G. Beijers; J.P. van den Bergh; F.H.M. van Osch

doi:10.1038/s41598-023-27879-8

Pulmonary function three to five months after hospital discharge for COVID-19: a single centre cohort study

T. Krueger, J. van den Heuvel, V. van van den Boogaart, R. van Zeeland, D.J. Mehagnoul-Schipper, D.G. Barten, L. Knarren, A.F.G. Maas^*, C.E. Wyers, D. Gach, A.M.W.J. Schols, R.J.H.C.G. Beijers, J.P. van den Bergh, F.H.M. van Osch^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Some COVID-19 survivors suffer from persistent pulmonary function impairment, but the extent and associated factors are unclear. This study aimed to characterize pulmonary function impairment three to five months after hospital discharge and the association with disease severity. Survivors of COVID-19 after hospitalization to the VieCuri Medical Centre between February and December 2020 were invited for follow-up, three to five months after discharge. Dynamic and static lung volumes, respiratory muscle strength and diffusion capacity were measured. The cohort comprised 257 patients after a moderate (n = 33), severe (n = 151) or critical (n = 73) COVID-19 infection with a median follow-up of 112 days (interquartile range 96-134 days). The main sequelae included reduced diffusion capacity (36%) and reduced maximal expiratory pressure (24%). Critically ill patients were more likely to have reduced diffusion capacity than moderate (OR 8.00, 95% CI 2.46-26.01) and severe cases (OR 3.74, 95% CI 1.88-7.44) and lower forced vital capacity (OR 3.29, 95% CI 1.20-9.06) compared to severe cases. Many COVID-19 survivors, especially after a critical disease course, showed pulmonary function sequelae, mainly DLCO impairments, three to five months after discharge. Monitoring is needed to investigate the persistence of these symptoms and the longer-term implications of the COVID-19 burden.

Original language	English
Article number	681
Number of pages	8
Journal	Scientific Reports
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41598-023-27879-8
Publication status	Published - 13 Jan 2023

Keywords

CONSEQUENCES
SEQUELAE

Access to Document

10.1038/s41598-023-27879-8Licence: CC BY

Cite this

Krueger, T., van den Heuvel, J., van van den Boogaart, V., van Zeeland, R., Mehagnoul-Schipper, D. J., Barten, D. G., Knarren, L., Maas, A. F. G., Wyers, C. E., Gach, D., Schols, A. M. W. J., Beijers, R. J. H. C. G., van den Bergh, J. P., & van Osch, F. H. M. (2023). Pulmonary function three to five months after hospital discharge for COVID-19: a single centre cohort study. Scientific Reports, 13(1), Article 681. https://doi.org/10.1038/s41598-023-27879-8

@article{1fcad92860124563b7ba4fef8123e42b,

title = "Pulmonary function three to five months after hospital discharge for COVID-19: a single centre cohort study",

abstract = "Some COVID-19 survivors suffer from persistent pulmonary function impairment, but the extent and associated factors are unclear. This study aimed to characterize pulmonary function impairment three to five months after hospital discharge and the association with disease severity. Survivors of COVID-19 after hospitalization to the VieCuri Medical Centre between February and December 2020 were invited for follow-up, three to five months after discharge. Dynamic and static lung volumes, respiratory muscle strength and diffusion capacity were measured. The cohort comprised 257 patients after a moderate (n = 33), severe (n = 151) or critical (n = 73) COVID-19 infection with a median follow-up of 112 days (interquartile range 96-134 days). The main sequelae included reduced diffusion capacity (36%) and reduced maximal expiratory pressure (24%). Critically ill patients were more likely to have reduced diffusion capacity than moderate (OR 8.00, 95% CI 2.46-26.01) and severe cases (OR 3.74, 95% CI 1.88-7.44) and lower forced vital capacity (OR 3.29, 95% CI 1.20-9.06) compared to severe cases. Many COVID-19 survivors, especially after a critical disease course, showed pulmonary function sequelae, mainly DLCO impairments, three to five months after discharge. Monitoring is needed to investigate the persistence of these symptoms and the longer-term implications of the COVID-19 burden.",

keywords = "CONSEQUENCES, SEQUELAE",

author = "T. Krueger and {van den Heuvel}, J. and {van van den Boogaart}, V. and {van Zeeland}, R. and D.J. Mehagnoul-Schipper and D.G. Barten and L. Knarren and A.F.G. Maas and C.E. Wyers and D. Gach and A.M.W.J. Schols and R.J.H.C.G. Beijers and {van den Bergh}, J.P. and {van Osch}, F.H.M.",

note = "Funding Information: This research was supported by the VieCuri Corona Foundation and Regio Noord-Limburg. Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = jan,

day = "13",

doi = "10.1038/s41598-023-27879-8",

language = "English",

volume = "13",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Krueger, T, van den Heuvel, J, van van den Boogaart, V, van Zeeland, R, Mehagnoul-Schipper, DJ, Barten, DG, Knarren, L, Maas, AFG, Wyers, CE , Gach, D , Schols, AMWJ , Beijers, RJHCG , van den Bergh, JP & van Osch, FHM 2023, 'Pulmonary function three to five months after hospital discharge for COVID-19: a single centre cohort study', Scientific Reports, vol. 13, no. 1, 681. https://doi.org/10.1038/s41598-023-27879-8

TY - JOUR

T1 - Pulmonary function three to five months after hospital discharge for COVID-19: a single centre cohort study

AU - Krueger, T.

AU - van den Heuvel, J.

AU - van van den Boogaart, V.

AU - van Zeeland, R.

AU - Mehagnoul-Schipper, D.J.

AU - Barten, D.G.

AU - Knarren, L.

AU - Maas, A.F.G.

AU - Wyers, C.E.

AU - Gach, D.

AU - Schols, A.M.W.J.

AU - Beijers, R.J.H.C.G.

AU - van den Bergh, J.P.

AU - van Osch, F.H.M.

PY - 2023/1/13

Y1 - 2023/1/13

N2 - Some COVID-19 survivors suffer from persistent pulmonary function impairment, but the extent and associated factors are unclear. This study aimed to characterize pulmonary function impairment three to five months after hospital discharge and the association with disease severity. Survivors of COVID-19 after hospitalization to the VieCuri Medical Centre between February and December 2020 were invited for follow-up, three to five months after discharge. Dynamic and static lung volumes, respiratory muscle strength and diffusion capacity were measured. The cohort comprised 257 patients after a moderate (n = 33), severe (n = 151) or critical (n = 73) COVID-19 infection with a median follow-up of 112 days (interquartile range 96-134 days). The main sequelae included reduced diffusion capacity (36%) and reduced maximal expiratory pressure (24%). Critically ill patients were more likely to have reduced diffusion capacity than moderate (OR 8.00, 95% CI 2.46-26.01) and severe cases (OR 3.74, 95% CI 1.88-7.44) and lower forced vital capacity (OR 3.29, 95% CI 1.20-9.06) compared to severe cases. Many COVID-19 survivors, especially after a critical disease course, showed pulmonary function sequelae, mainly DLCO impairments, three to five months after discharge. Monitoring is needed to investigate the persistence of these symptoms and the longer-term implications of the COVID-19 burden.

AB - Some COVID-19 survivors suffer from persistent pulmonary function impairment, but the extent and associated factors are unclear. This study aimed to characterize pulmonary function impairment three to five months after hospital discharge and the association with disease severity. Survivors of COVID-19 after hospitalization to the VieCuri Medical Centre between February and December 2020 were invited for follow-up, three to five months after discharge. Dynamic and static lung volumes, respiratory muscle strength and diffusion capacity were measured. The cohort comprised 257 patients after a moderate (n = 33), severe (n = 151) or critical (n = 73) COVID-19 infection with a median follow-up of 112 days (interquartile range 96-134 days). The main sequelae included reduced diffusion capacity (36%) and reduced maximal expiratory pressure (24%). Critically ill patients were more likely to have reduced diffusion capacity than moderate (OR 8.00, 95% CI 2.46-26.01) and severe cases (OR 3.74, 95% CI 1.88-7.44) and lower forced vital capacity (OR 3.29, 95% CI 1.20-9.06) compared to severe cases. Many COVID-19 survivors, especially after a critical disease course, showed pulmonary function sequelae, mainly DLCO impairments, three to five months after discharge. Monitoring is needed to investigate the persistence of these symptoms and the longer-term implications of the COVID-19 burden.

KW - CONSEQUENCES

KW - SEQUELAE

U2 - 10.1038/s41598-023-27879-8

DO - 10.1038/s41598-023-27879-8

M3 - Article

C2 - 36639404

SN - 2045-2322

VL - 13

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 681

ER -